Your browser is no longer supported. Please, upgrade your browser.
Settings
ALXN Alexion Pharmaceuticals, Inc. daily Stock Chart
ALXN [NASD]
Alexion Pharmaceuticals, Inc.
IndexS&P 500 P/E18.42 EPS (ttm)6.04 Insider Own0.10% Shs Outstand223.30M Perf Week-2.50%
Market Cap24.83B Forward P/E9.89 EPS next Y11.25 Insider Trans-2.22% Shs Float220.77M Perf Month0.37%
Income1.36B PEG1.14 EPS next Q2.54 Inst Own96.10% Short Float1.65% Perf Quarter2.11%
Sales4.74B P/S5.24 EPS this Y-95.70% Inst Trans-2.80% Short Ratio1.97 Perf Half Y-7.83%
Book/sh46.43 P/B2.40 EPS next Y8.41% ROA10.30% Target Price149.45 Perf Year-3.01%
Cash/sh9.92 P/C11.21 EPS next 5Y16.21% ROE14.90% 52W Range92.56 - 141.86 Perf YTD14.22%
Dividend- P/FCF16.73 EPS past 5Y-40.60% ROI0.40% 52W High-21.61% Beta1.68
Dividend %- Quick Ratio3.40 Sales past 5Y21.60% Gross Margin92.00% 52W Low20.14% ATR3.57
Employees2656 Current Ratio4.00 Sales Q/Q23.00% Oper. Margin34.30% RSI (14)52.36 Volatility4.61% 2.97%
OptionableYes Debt/Eq0.25 EPS Q/Q35.40% Profit Margin31.00% Rel Volume0.90 Prev Close112.48
ShortableYes LT Debt/Eq0.24 EarningsJan 22 BMO Payout0.00% Avg Volume1.84M Price111.20
Recom1.90 SMA200.17% SMA505.02% SMA200-6.32% Volume1,655,364 Change-1.14%
Nov-12-19Initiated SunTrust Buy $125
Oct-17-19Resumed BofA/Merrill Buy $130
Sep-26-19Initiated William Blair Outperform
Jul-31-19Resumed JP Morgan Overweight $172
May-23-19Resumed Goldman Neutral $142
May-23-19Resumed Citigroup Buy
May-23-19Initiated Wedbush Outperform
Apr-10-19Resumed Raymond James Outperform $161
Mar-27-19Reiterated RBC Capital Mkts Outperform $165 → $186
Mar-21-19Reiterated Guggenheim Neutral $135
Feb-22-19Initiated Guggenheim Neutral $135
Aug-07-18Downgrade Stifel Buy → Hold $154 → $130
Feb-05-18Upgrade Evercore ISI In-line → Outperform
Jan-18-18Resumed Credit Suisse Outperform $147
Jan-04-18Downgrade Raymond James Strong Buy → Outperform
Dec-18-17Upgrade Robert W. Baird Neutral → Outperform $150
Oct-23-17Resumed Piper Jaffray Overweight $170
Sep-15-17Initiated RBC Capital Mkts Outperform $161
Sep-13-17Reiterated Leerink Partners Outperform $170 → $182
Sep-13-17Reiterated Deutsche Bank Buy $153 → $158
Dec-10-19 03:44PM  Top stock picks for 2020: The best of the biggest MarketWatch
11:47AM  The 13 Best Health-Care Stocks to Buy for 2020 Kiplinger
09:24AM  Zacks.com featured highlights include: Quanta Services, Alexion Pharmaceuticals, Jazz Pharmaceuticals and Changyou.com Zacks
Dec-09-19 08:36AM  Alexion (ALXN) Looks Good: Stock Adds 6% in Session Zacks
06:18AM  Create a Standout Portfolio With These 4 Low P/CF Stocks Zacks
Dec-06-19 04:33PM  An Activist Investor Pushed This Biotech To Sell Why It Refused Investor's Business Daily +6.02%
12:22PM  The Dow Is Up 336 Points Because the Jobs Report Was Just That Good Barrons.com
10:05AM  Alexion Rejects Elliott Affiliates Push to Put Biotech on Block Bloomberg
09:37AM  Alexion stocks rises on decision not to consider a sale MarketWatch
09:18AM  Zacks.com featured highlights include: Alexion Pharmaceuticals, OpGen, Integer, ReWalk Robotics and Civeo Zacks
09:08AM  UPDATE 3-Alexion Pharma rejects Elliott's push for "proactive sale" Reuters
08:42AM  Alexion Pharmaceuticals rejects Elliott push for "proactive sale" Reuters
08:30AM  Alexion Issues Statement on Path to Value Creation Business Wire
05:49AM  Deals of the day-Mergers and acquisitions Reuters
Dec-05-19 12:56PM  The Dow Goes Negative Despite a Glimmer of Hope on Trade Barrons.com -6.96%
08:02AM  5 Discounted PEG Stocks for GARP Investors Zacks
06:21AM  Adopt Rising P/E Technique With These 5 Top-Ranked Stocks Zacks
Dec-04-19 11:40AM  ALXN vs. ILMN: Which Stock Is the Better Value Option? Zacks
Nov-29-19 11:49AM  8 Stocks Paul Tudor Jones Continues To Buy GuruFocus.com
Nov-28-19 10:19PM  Hedge Funds Are Getting Crazy About Alexion Pharmaceuticals, Inc. (ALXN) Insider Monkey
Nov-27-19 10:09AM  Biotech Stock Roundup: CBAY Falls, CCXI Gains, Amgen Acquires Otezla & More Zacks
08:24AM  The Zacks Analyst Blog Highlights: Vertex, Biogen, BioMarin and Alexion Zacks
Nov-26-19 04:31PM  Alexion to Present at the 2019 Evercore ISI HealthCONx Business Wire
06:07AM  4 Big Drug Stocks Ripe for Takeover After NVS-MDCO Deal Zacks
Nov-25-19 10:11AM  Billionaire Ray Dalio Snaps Up These 3 Strong Buy Stocks TipRanks
09:18AM  Alexion Gets Approval for Label Expansion of Soliris in Japan Zacks
Nov-22-19 09:31AM  Alexion (ALXN) Up 3.3% Since Last Earnings Report: Can It Continue? Zacks
08:30AM  SOLIRIS® (eculizumab) Receives Approval in Japan for the Prevention of Relapse in Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD) Business Wire
06:38AM  Alexion Pharmaceuticals Does Not Look Boston Strong TheStreet.com
Nov-21-19 02:41PM  Biogen, Novartis named in settlement between foundation, federal prosecutors American City Business Journals
Nov-20-19 09:50AM  The Zacks Analyst Blog Highlights: Alexion Pharmaceuticals, Vertex Pharmaceuticals, Incyte and Regeneron Pharmaceuticals Zacks
09:50AM  Achillion's (ACHN) Danicopan Gets EMA's PRIME Tag for PNH Zacks
Nov-19-19 10:14AM  4 Big Biotech Stocks Worth Considering Post Q3 Earnings Zacks
Nov-18-19 06:32PM  Miller Value Partners Likes These Two Stocks; Bearish on One Insider Monkey
09:30AM  ALXN vs. CBM: Which Stock Should Value Investors Buy Now? Zacks
09:18AM  Zacks.com featured highlights include: Avinger, Alexion Pharmaceuticals, CyberArk Software, Organovo and Qualys Zacks
Nov-15-19 07:06AM  What Bargain Hunting? Tap 5 Stocks With Rising P/E Zacks
Nov-14-19 10:46AM  The Zacks Analyst Blog Highlights: AMETEK, Thermo Fisher Scientific, IQVIA, Lowe's Companies and Alexion Pharmaceuticals Zacks
09:58AM  Alexion (ALXN) Up 10 % YTD on Soliris & Ultomiris Strength Zacks
08:45AM  Alexion (ALXN) is an Incredible Growth Stock: 3 Reasons Why Zacks
Nov-13-19 07:54AM  5 Most-Loved S&P 500 Stocks on Wall Street Zacks
06:30AM  Alexion to Present at the 2019 Stifel Healthcare Conference Business Wire
Nov-12-19 12:23PM  Sales winners in the third quarter include Netflix, Autodesk and PayPal MarketWatch
11:37AM  Buy Big Biotech But Not Gilead, Analyst Says Barrons.com
Nov-11-19 12:51PM  Drugmaker Amgen cuts a quarter of its Kendall Square research staff American City Business Journals
09:15AM  Celgene (CELG) Hits 52-Week High, Can the Run Continue? Zacks
Nov-08-19 08:00AM  Pharma Sector Tops in October: Best ETFs & Stocks Zacks
Nov-06-19 10:30AM  Alexion Announces Data Presentations at 61st American Society of Hematology Annual Meeting Business Wire
Nov-04-19 05:05PM  Biotech ETFs in Focus on Impressive Q3 Earnings Results Zacks
Nov-01-19 09:30AM  Has Alexion Pharmaceuticals (ALXN) Outpaced Other Medical Stocks This Year? Zacks
Oct-31-19 11:36AM  The Zacks Analyst Blog Highlights: Alexion, Amgen, Gilead and AMAG Zacks
09:30AM  ALXN or CBM: Which Is the Better Value Stock Right Now? Zacks
06:52AM  Try Rising P/E Investing With 5 Top-Ranked Stocks Zacks
06:30AM  Dicerna ropes in Roche on gene-silencing deal worth up to $1.67B American City Business Journals
Oct-30-19 10:56AM  Biotech Stock Roundup: Q3 Earnings Beat at ALXN & AMGN, Pipeline Updates & More Zacks
10:43AM  Healthcare ETFs Win in October: Here's Why Zacks
06:29AM  Should You Be Worried About Alexion Pharmaceuticals, Inc.'s (NASDAQ:ALXN) 14% Return On Equity? Simply Wall St.
Oct-29-19 03:02PM  SHAREHOLDER ALERT: WeissLaw LLP Reminds HLND, TNCB, ACHN, RARX Shareholders About Its Ongoing Investigations GlobeNewswire
08:45AM  Here is Why Growth Investors Should Buy Alexion (ALXN) Now Zacks
Oct-28-19 11:59AM  Drug/Biotech Stock Q3 Earnings Due on Oct 29: MRK, PFE & More Zacks
11:18AM  3 Perfect 10 Biotech Stocks to Buy Amid Volatile Market Environment TipRanks
Oct-25-19 09:37AM  3 Strong Buy Stocks Top Investors Are Buying TipRanks
Oct-24-19 10:40PM  Edited Transcript of ALXN earnings conference call or presentation 23-Oct-19 12:00pm GMT Thomson Reuters StreetEvents
11:09AM  The Zacks Analyst Blog Highlights: Biogen, Vertex, Amgen, Alexion and Achillion Pharmaceuticals Zacks
09:31AM  Company News For Oct 24, 2019 Zacks
Oct-23-19 04:03PM  Two Drugmakers Beat Earnings Forecasts So Why Did One Topple? Investor's Business Daily +7.40%
12:14PM  The Dow Scratches Out a Gain as Investors Sort Through Earnings Jumble Barrons.com
11:31AM  Two Drugmakers Beat Earnings Forecasts So Why Did One Topple? Investor's Business Daily
11:26AM  Alexion (ALXN) Beats on Q3 Earnings, Lifts 2019 Guidance Zacks
10:10AM  Biotech ETFs Surge on a Flurry of Positive News Zacks
09:58AM  Alexion Stock Is Rising on an Earnings Beat, Better Guidance, Buybacks Barrons.com
09:45AM  Biotech Stock Roundup: BIIB Up on AD Data, ALXN to Buy ACHN & Other Pipeline Updates Zacks
07:55AM  Alexion Pharmaceuticals (ALXN) Q3 Earnings and Revenues Top Estimates Zacks
06:56AM  Alexion Rises After Drug Developer Beats Earnings Expectations TheStreet.com
06:30AM  Alexion Reports Third Quarter 2019 Results Business Wire
06:00AM  Alexion Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
02:32AM  Alexion Earnings, Revenue Beat in Q3 Investing.com
Oct-22-19 11:32AM  Drug/Biotech Stock Q3 Earnings on Oct 23: LLY, ALXN & More Zacks
10:18AM  What's in Store for IDEXX Laboratories' (IDXX) Q3 Earnings? Zacks
10:00AM  What's in the Cards for Sarepta (SRPT) This Earnings Season? Zacks
Oct-21-19 10:24AM  Is Walgreens Boots (WBA) Likely to Disappoint in Q4 Earnings? Zacks
09:33AM  Alexion Gets FDA Approval for Label Expansion of Ultomiris Zacks
Oct-18-19 08:25PM  UPDATE 1-FDA approves Alexion's Ultomiris for another rare blood disease Reuters
07:52PM  FDA approves Alexion's Ultomiris for another rare blood disease Reuters
07:45PM  Alexion Receives FDA Approval for ULTOMIRIS® (ravulizumab-cwvz) for Atypical Hemolytic Uremic Syndrome (aHUS) Business Wire
04:50PM  SHAREHOLDER ALERT: WeissLaw LLP Investigates Achillion Pharmaceuticals, Inc. PR Newswire
12:05PM  Will Soliris Aid Growth for Alexion (ALXN) in Q3 Earnings? Zacks
11:17AM  Will Strong HIV Sales Drive Gilead's (GILD) Q3 Earnings? Zacks
11:02AM  What's in Store for Thermo Fisher (TMO) in Q3 Earnings? Zacks
07:04AM  Alexion to Buy Achillion for $930M, Strengthen PNH Franchise Zacks
Oct-16-19 03:05PM  Montco biotech firm sold for $930M, shares soar American City Business Journals -5.06%
01:53PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Achillion Pharmaceuticals, Inc. to Alexion Pharmaceuticals, Inc. is Fair to Shareholders GlobeNewswire
11:43AM  Alexion makes $930M acquisition in bid to bolster blockbuster drug American City Business Journals
11:15AM  Achillion Pharmaceuticals Stock Soars on Deal to Be Acquired by Alexion Barrons.com
10:32AM  Alexion Pharmaceuticals (ALXN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release Zacks
09:30AM  Is Alexion Pharmaceuticals (ALXN) Stock Outpacing Its Medical Peers This Year? Zacks
08:50AM  Achillion (ACHN) Alert: Johnson Fistel Investigates Proposed Sale of Achillion Pharmaceuticals; Are Shareholders Getting a Fair Deal? PR Newswire
07:25AM  Alexion To Acquire Achillion Pharma For $930M Benzinga
07:15AM  Achillion Pharmaceuticals' stock rockets after Alexion Pharmaceuticals $930 million buyout deal MarketWatch
06:41AM  Drugmaker Alexion to buy biotech Achillion in $930 mln deal Reuters
Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis. It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company conducts Phase III clinical trials for ALXN 1210 (IV) for the treatment of PNH and aHUS; ALXN1210 (Subcutaneous), which is in Phase I for PNH and aHUS; and Soliris (eculizumab) for the treatment of myasthenia gravis and neuromyelitis optica spectrum disorder. Further, it develops ALXN1840 that is in Phase III clinical trials for the treatment of Wilson disease; and ALXN1830, which is in Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc. to use drug-delivery technology in the development of subcutaneous formulations for its portfolio of products; collaboration with Dicerna Pharmaceuticals, Inc. to discover and develop RNAi therapies for complement-mediated diseases, as well as with Zealand Pharma A/S; strategic agreement with Caelum Biosciences, Inc. to advance the development of CAEL-101 for light chain amyloidosis; agreement with Stealth BioTherapeutics Corp. to co-develop and commercialize therapy for mitochondrial diseases; and a partnership with Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Franchini Indrani LallEVP, Chief Compliance OfficerJul 01Sale132.784,500597,51029,627Jul 02 04:41 PM
SARIN ARADHANAChief Strategy & Business OffJun 21Sale132.0057876,29630,201Jun 24 04:45 PM
BAKER BROS. ADVISORS LPDirectorMay 30Sale120.9757,4496,949,754952,874May 30 05:16 PM
BAKER BROS. ADVISORS LPDirectorMay 29Sale122.20119,06214,548,851959,035May 30 05:16 PM
BAKER BROS. ADVISORS LPDirectorMay 28Sale126.53123,48915,624,859971,803May 30 05:16 PM
Bazarko DanielSVP, Controller, CAOFeb 14Sale126.002,000252,0005,020Feb 19 07:29 PM
HANTSON LUDWIGCEODec 31Sale95.853,244310,937150,696Jan 03 06:07 PM